Home Search

ctxr - search results

If you're not happy with the results, please do another search

Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...

We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10...
Biotech Stock Review

Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...

Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE
@bryteeyes3

Citius (CTXR). Dang Flippers!

Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
@NCI

Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...

- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of...
Issam Radd

Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).

Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR) Summary
Biotech Stock Review. Citius, CTXR

More Great News From Citius Pharma (CTXR).

UPDATED CHART 6-15-21 Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News

Citius Pharma (CTXR) Updates Shareholders.

Citius Update Stem Cell Study Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society...
Citius, Leonard Mazur

Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.

https://youtu.be/vMIy8xWLOKI?t=3699 Starts at 1 Hour Mark. INSIDER HOLDINGS
Citius

Wall Street Showing Love. Hepion Pharma (HEPA), Citius Pharma (CTXR) Raise $166 Million.

Hepion (HEPA) Banked $88 Million Yesterday, Citius (CTXR) Banks $78 Million Today. We're beginning to believe (and...

Latest article

ARK VS. SARK | PAST STANCES

Long Ark Innovation 10/3/2022 | $37.90 #ARK, #ARKK, #SARK

ARK vs. SARK

Ever get really, really bearish and really, really wish you could find a simple way to make money in a bear market?

Adding ‘Internet of Things,’ Direct Communications (DCSX) $1.17 to the Watch List.

Chris Bursey, Member of Verizon's Internet of Things (IOT) Advisory Council, Charges Ahead as CEO of Direct Communication (DCSX).